 AzurRx BioPharma Inc NASDAQ: AZRX has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at 229 million, including milestone payments. First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases IBD. 